COMPASS Pathways plc

The current price of CMPS is $7.81 — it has decreased by 9.19% since the previous close. Data as of Nov 5, 2026.

CMPS is down 33.94% over the past week, down 32.67% over the past month and up 42.26% over the past year. The price is below its 200-day moving average of $10.42.

Analysts' average 12-month price target for CMPS is $19.56, which implies 150.45% upside from the current price. Individual estimates range from $13.00 to $25.00.

Of the 16 analysts covering COMPASS Pathways plc, 3 rate it a strong buy, 12 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

COMPASS Pathways plc has a market capitalization of $1.11B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, COMPASS Pathways plc posted a loss of $0.31 per share against an estimate of -$0.39, beating expectations by 20.51%. Upcoming reports are listed in the earnings calendar.

COMPASS Pathways plc has not paid any dividends over the past year.

Companies most comparable to COMPASS Pathways plc include Praxis Precision Medicines, Inc., Definium Therapeutics, Inc., Acadia Pharmaceuticals Inc., Denali Therapeutics Inc. and Harmony Biosciences Holdings, Inc.

In the latest trading session CMPS moved between $7.78 and $8.61, a range of 10.63% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of COMPASS Pathways plc shows a sell rating today. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for COMPASS Pathways plc is sell. Technical ratings are indicators, not investment advice.

Over the past 52 weeks CMPS has traded between $4.88 and $15.87. The current price is 50.79% below its 52-week high.